A randomized, double-blind, placebo-controlled trial was conducted to (1) evaluate efficacy and safety of transdermal testosterone gel (AndroGel) for hypogonadal men in Taiwan, and (2) observe improvements in sexual function through international index of erectile function (IIEF) scores. Eligible hypogonadal men were randomized to receive 50 mg/day transdermal testosterone gel (TTG) or placebo for 3 months. Primary end point was change from baseline in total testosterone (TT) and free testosterone (FT). Secondary end points were change from baseline in serum hormone levels (such as dihydrotestosterone (DHT), estradiol (E2), luteinizing hormone (LH), folliclestimulating hormone (FSH) and sex-hormone-binding globulin (SHBG)) and changes in IIEF scores. Safety evaluations included adverse events (AEs) and skin irritation assessment. Compared with baseline, the TTG group (n ¼ 20) had statistically significant increases in mean TT levels at month 1 (P ¼ 0.024) and month 2 (P ¼ 0.025), but no significant changes at month 3. TT levels in the placebo group (n ¼ 18) showed no statistically significant change at any visit. Changes in FT levels paralleled changes in TT levels in both groups. TTG group IIEF scores were significantly increased at month 3 (P ¼ 0.01), compared with a decline in placebo scores. No drug-related AEs occurred in the TTG group; the placebo group had 2 AEs (mild skin rash). In conclusion, TTG effectively restores serum TT and FT levels to a normal physiological range for hypogonadal men in Taiwan and improves sexual function.
Introduction
Testosterone replacement therapy or androgen replacement therapy (ART), in hypogonadal men has been well studied. [1] [2] [3] [4] [5] Symptoms associated with male hypogonadism are sexual dysfunction, fatigue, loss of energy, mood depression, change of body composition and osteoporosis. 1, 3, 6, 7 The aim of ART is to restore serum testosterone levels to a normal physiological range by administering exogenous testosterone to maintain sexual function, energy, mood and muscle development, as well as to improve bone density. 7, 8 Various forms of testosterone therapy are currently available to treat hypogonadism in men, but many of these formulations have limitations. Orally available testosterone (such as methylated androgens) is relatively insoluble and associated with significant first-pass metabolism, which results in limited effectiveness and a poor safety profile, although testosterone undecanoate has better safety and efficacy. [9] [10] [11] Intramuscular depot injections are inconvenient and produce wide fluctuations in testosterone concentrations. [7] [8] [9] [10] 12 Although transdermal testosterone patches, available in both scrotal and non-scrotal forms, can produce a more consistent delivery of testosterone into the systemic circulation, they are associated with adverse skin reactions at the patch site and thus have a reduced compliance rate. 2, 3, 11, 13 Transdermal testosterone gel (TTG, Androgel), a 1% testosterone hydroalcoholic gel, provides continuous delivery of testosterone for 24 h after a single daily application. 14 Applied over a large area of skin in an open system, TTG is associated with minimal (B5.5%) skin irritation. 1, 2, 7, 8, 11, [13] [14] [15] The purpose of the present study was to evaluate the efficacy and safety of 50 mg/day of TTG, applied on non-scrotal skin, for hypogonadal men in Taiwan. Although TTG has been shown to be effective in Caucasian men, there are little data regarding its efficacy in Asian population. To our knowledge, this was the first study to determine the clinical and biochemical effect of TTG in Asian society through a clinical trial. A special aim was to observe any improvement of the subjects' erectile dysfunction through their scores on the international index of erectile function (IIEF) questionnaire.
Subjects and methods

Study design
This was a double-blind, randomized, placebocontrolled, 3-month study of TTG (AndroGel; 50 mg/day) used as ART in hypogonadal men in Taiwan. The study was conducted between November 2002 and November 2004, at the Taipei Medical University Hospital and Shin-Kong Wu Ho Su Memorial Hospital in Taipei, Taiwan. The Institutional Review Board approval was obtained before conducting this prospective study. All subjects signed an approved informed consent form. The primary end points were a change from baseline in total testosterone (TT) and free testosterone (FT) at 3 months. Secondary end points were change from baseline in serum hormone levels (dihydrotestosterone (DHT), estradiol (E2), luteinizing hormone (LH), follicle-stimulating hormone (FSH), and sexhormone-binding globulin (SHBG)) and changes in IIEF scores at 3 months. Safety evaluations included adverse events (AEs), assessment of skin irritation, laboratory tests, physical examination, vital signs, and prostate (digital rectal examination (DRE) and prostate-specific antigen (PSA) test) and urine flow rate evaluations.
At the initial screening visit (À28 to À1 day), all subjects who fulfilled the selection criteria had demographic data collected, a medical history, physical examination, vital signs, laboratory examinations, serum prolactin, urine flow rate evaluation and a prostate evaluation (DRE and PSA). For men with a suspicious prostatic mass, an optional transrectal ultrasound was conducted. TT and FT were checked twice, a week apart, before men were enrolled. Each subject completed the erectile function (EF) domain of IIEF or IIEF-5 and international prostate symptom score (IPSS) questionnaires. Concomitant medications, nondrug treatment and pretreatment events were recorded.
At the baseline assessment (visit 2), eligible subjects were randomized to receive 50 mg/day TTG (group A) or placebo (group B). TT and FT were checked again. Physical examination and evaluations for vital signs, DHT, E2, SHBG, LH and FSH were performed. After the treatment medication was applied, a skin irritation assessment was made.
At each of three treatment visits, approximately 30 days (73 days) apart, the following tests were done: TT and FT measurements, physical examination, vital signs, laboratory examination, skin irritation assessment, concomitant medications, nondrug treatment and AEs. IIEF questionnaires were completed for each subject at the last visit.
Subjects
A total of 77 male patients were enrolled from the above two institutions and were screened for symptoms of hypogonadism through a medical history, physical examination and laboratory tests, including basal hormone levels. Men, between 20 and 75 years of age, who were diagnosed with testosterone deficiency that required testosterone replacement were considered eligible. Further, among them, the only eligible subjects were men who had never taken ART or had withdrawn from testosterone supplements (including food supplements like dehydroepiandrosterone (DHEA)) for 6 weeks before the study began. Hypogonadal men were eligible if their morning serum testosterone concentrations were o300 ng/dl. If TT was X300 ng/ dl, FT concentrations were to be o8.7 pg/ml.
Men were excluded from the study if they had abnormal prostate levels of IPSS 425, prostatic masses or induration on rectal examination or elevated levels of PSA44 ng/ml or maximum urine flow rate of o10 ml/s or hematoacrit 450%. A subject was also excluded if he had a history or evidence of pulmonary, renal, hepatic, neurological, musculoskeletal or cardiovascular disease that might affect the outcome of the study or would place him at risk. Subjects were also excluded if they were taking drugs that might interfere with the study results (for example, paroxetine, clomipramine, antiandrogen, estrogens, p450 enzyme inducers, barbiturates, oxyphenbutazone, adrenocorticotropic hormone or corticosteroids). Other reasons for exclusion included a major psychiatric illness, sleep apnea, significant systemic illness, active alcoholism, history of drug abuse within the past 5 years, body mass index (BMI)427.0 or o18.5, generalized skin disease that might affect the absorption of testosterone or prolactin levels 440 mcg/l. Some men were excluded from this study because of their wives' disagreements.
Subjects could be removed or terminated from the study if the investigator believed that the patient's Transdermal testosterone gel increases serum testosterone levels HS Chiang et al health or well-being was threatened by continuation because of AEs or intercurrent conditions that required discontinuation of the study medication.
Study drug and application instructions TTG (Androgel, Montrouge, France) is a transparent, colorless, water-soluble gel. Group A received testosterone gel containing 1.0% testosterone, ethanol (96%), purified water, sodium hydroxide and isopropyl myristate (50 mg testosterone/5 g sachet).
Group B received a placebo gel. All study medication was supplied by Orient Europharma Co., Ltd, Taipei, Taiwan. Subjects were instructed to apply the gel once a day to two application sites, either shoulders and upper arms and/or the abdomen. Alternate application sites were continued throughout the study. The gel was not to be applied to the genitals. If a subject developed skin irritation at the application site, he was advised to apply corticosteroid cream before applying the gel.
Statistical methods
Descriptive statistics and 95% confidence intervals (CI) were used to summarize continuous variables. Proportion was used to summarize categorical variables. All statistical tests for efficacy end points and other clinical end points were two-sided and evaluated at 0.05 level of significance. Moreover, based on means and variances of two independent samples with a ¼ 0.05, two-tails and sample size of each group being 20, power were calculated. The intent-to-treat (ITT) population, defined as all randomized subjects who had taken at least one dose of medication and had at least one follow-up visit, was the basis for efficacy and safety evaluations.
Two-way analyses of variance (ANOVA) was used to compare the primary and secondary efficacy end points, including TT, FT, DHT, E2, SHBG, LH, FSH, IIEF and IPSS, and safety parameters between the two treatment groups; paired t-test was used to test changes from baseline within each treatment group. Since the comparison in different time point has been considered in ANOVA, the individual paired t-test was not adjusted for multiple comparisons.
Results
Subject demographic and baseline characteristics
A total of 40 eligible men were randomized to receive TTG 50 mg/day (group A, n ¼ 20) or placebo (group B, n ¼ 20). Three subjects from the placebo group were withdrawn early because of AEs, and one from the placebo group withdrew the consent. There were 38 subjects in the ITT population for efficacy and safety evaluations, and 36 patients (20 in group A, 16 in group B) completed the 3-month study. The reasons of exclusion included relatively high screening TT level (14) , elevated PSA level (8), low urinary flow rate (4) and other nonmedical reasons including their wives' disagreements (12) .
Demographics and baseline characteristics of the two groups were comparable, with no statistically significant differences for any variable. Subjects in both groups ranged in age from 20 to 74 years, in weight from 56 to 88 kg, in height from 157 to 192 cm, and in BMI from 19.0 to 26.9. Men in the placebo group were older (56.1714.6 years) than those in the treatment group (47.9717.0), but the difference was not statistically significant.
Primary efficacy results TT. At baseline of TT levels, there were no significant differences between TTG group and placebo group (ANOVA between-group, P ¼ 0.397). Changes from baseline in mean serum TT levels for the two groups are shown in Table 1 . Compared with baseline, the TTG group at month 1 (visit 3) had a statistically significant increase (P ¼ 0.024) in mean serum TT levels (179.67328.7 ng/dl), whereas the placebo group showed little change from baseline TT levels with no statistical or clinical significance. The same trend continued to month 2: the TTG group had a statistically significant increase in mean TT levels from baseline (171.17313.9 ng/dl, P ¼ 0.025), whereas the placebo group did not. At month 3, however, mean TT levels in the TTG group declined slightly, and the change from baseline was not statistically significant (P ¼ 0.141). In the placebo group, the TT levels remained approximately the same throughout the study, showing no statistically significant change from baseline at any Transdermal testosterone gel increases serum testosterone levels HS Chiang et al visit. Between treatment group, changes in mean TT levels from baseline were not statistically significant at any study visit.
FT. Changes from baseline in FT for the two groups are shown in Table 2 . (ANOVA, P ¼ 0.445). Compared with baseline, the TTG group at month 1 (visit 3) had a statistically significant increase (P ¼ 0.020) in mean serum FT levels (4.7278.31 pg/ml), whereas the placebo group showed little change from baseline in FT levels without statistical significance. The same trend continued to month2: the TTG group had a statistically significant increase in mean FT levels from baseline (9.32717.39 pg/ml; P ¼ 0.004), whereas the placebo group did not. At month 3, however, mean FT levels in the TTG group declined slightly, and the change from baseline was not statistically significant (P ¼ 0.059). Between treatment group, changes in mean FT levels from baseline were statistically significant at month 2 (P ¼ 0.014), but not at month 1 or month 3.
Secondary efficacy results Secondary end points: DHT, E2, SHBG, LH, FSH. Subjects in both groups had comparable levels of DHT, E2, SHBG, LH and FSH at baseline, with no statistically significant differences between them (Table 3 ) (ANOVA, P ¼ 0.879, 0.297, 0.336, 0.939, 0.948, respectively). Serum DHT levels in the TTG group showed a statistically significant increase at month 3 (P ¼ 0.031) compared with baseline, whereas serum DHT levels in the placebo group decreased but without statistical significance. A similar trend was observed for serum LH and FSH levels: at month 3, the TTG group showed statistically significant reductions from baseline of P ¼ 0.014 and 0.019, respectively; changes in the placebo group were not statistically significant for either variable. Between-treatment group changes from baseline to month 3 were statistically and significantly different for DHT (P ¼ 0.034) and LH levels (P ¼ 0.013), but not for E2, FSH or SHBG levels.
Total scores for IIEF and IPSS questionnaires
At baseline, mean scores of the EF domain of IIEF (IIEF-5) and IPSS questionnaires were comparable across treatment groups without statistical significance (Table 4 ) (ANOVA, P ¼ 0.218). However, at month 3, the scores of the TTG group on the IIEF Transdermal testosterone gel increases serum testosterone levels HS Chiang et al index were statistically and significantly increased over baseline (P ¼ 0.01), compared with no change in scores for the placebo group. The changes between the TTG and placebo groups were also statistically and significantly different at month 3 (P ¼ 0.01). With regard to the IPSS index, none of the changes at 3 months were statistically and significantly different. Both groups showed reductions in the IPSS scores at month 3, but the changes were not statistically significant.
Safety results
Of the 38 subjects, 16 (42%) reported one or more AEs, 8 subjects (40%) in the TTG group (n ¼ 20) and 8 (44%) in the placebo group (n ¼ 18). A total of 32 AEs were reported, 13 in the TTG group and 19 in the placebo group (Table 5) . Most were short-term potentially drug-related, such as back pain (two episodes), abdominal discomfort (two), constipation (two), hyperglycemia (two), cough (two) and eye disorder (two) in the TTG group, while back pain (two), abdominal discomfort (two), microscopic hematuria (four), hyperlipidemia (two), and anxiety (two) in the placebo group. Two other subjects (5%) in the placebo group reported severe AEs (kidney calculus and gastrointestinal cancer), but these were not drug-related. Two AEs (5%), both in the placebo group, were drug-related; one subject reported moderate skin erythema on both arms, buttocks and head skin; the other reported a mild skin rash on the bilateral upper arms. Subjects in the TTG group did not report any drug-related AEs.
No change in the vital signs can be detected in the serial visits. Because testosterone replacement may have potentially negative effects on prostate tissue, with the risk of development of prostate tumors or benign tissue growth, 16 DRE and PSA were monitored. All subjects in the TTG group had normal DRE at baseline and after treatment.
Discussion
This pilot study was a prospective, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of 50 mg/day TTG in 20 hypogonadal men in Taiwan during a 3-month study. Although TTG has been shown to be effective in Caucasian men, there are few data regarding its efficacy in Asian population. Moreover, this study was to observe whether there was any improvement in the subjects' erectile dysfunction by using their scores on the IIEF questionnaire. As expected, at baseline of TT and FT levels, there were no statistical difference between cases and controls. Based on results of the TT and FT comparisons, continuous TTG application was effective in producing normal serum levels of testosterone. There were statistically significant increase in FT after first and second months of application of the AndroGel. Although the measurement was higher in month 3, statistical significance was not achieved. This may be due to small sample size, poor compliance in some patients and scattered data distribution or variability in T assays. Another possible implication is that hormonal replacement therapy may work in Abbreviation: TTG, transdermal testosterone gel.
Transdermal testosterone gel increases serum testosterone levels HS Chiang et al a short-term and temporary manner, it suggests that dose escalation from 5 to 10 g may be necessary for some patients. The decline in the elevating TT and FT levels was observed in month 3, while the IIEF is still at a level of significant increase. The disparity of biochemical measurements and the clinical symptoms needs a long-term study to verify. Notably, the scores of IIEF in the TTG group were significantly better at 3 months compared to their baseline values and also with the placebo group values at baseline and at 3 months. These changes indicate that TTG treatment improved the erectile dysfunction of these Taiwanese men. Further support for these observations came from recent studies on the relationship between testosterone supplementation and erectile dysfunction (ED). [16] [17] [18] [19] Until the last decade such evidence was unclear; the role of androgen supplementation in sexual function was believed to be derived from its effect on sexual interest and libido. 16 Furthermore, experimental animal and human studies have demonstrated that androgens, primarily testosterone, play an important role in the vasculature of the corpus cavernosum of the penis. Animal studies in the rat and rabbit have demonstrated a variety of biochemical changes in erectile function and structure that depend on adequate androgen levels. [17] [18] [19] In humans, the effects of testosterone supplementation have been studied in hypogonadal men with ED. 20 In 15 men with severe hypogonadism and a control group of 20 men with psychogenic ED, testosterone treatment for 6 months with a 5 mg/day patch normalized nocturnal penile tumescence parameters and improved penile vascularization. 20 Through conducting the penile color duplex ultrasound, these improvements were observed by the detection of an increase in peak systolic velocity (PSV) and a decrease in end diastolic velocity (EDV), resulting in an increase in resistive index (RI). The authors concluded that testosterone treatment has an important regulatory role in the central and peripheral vascular control of erection.
Our study is the first to show the effectiveness of TTG for the improvement of sexual function in Asian men. To date, other such studies have been performed on American 1, 2, 5, 7, 8, 11 and German men. 15 In the United States, the Testosterone Gel Study Group 5, 7, 8 evaluated 163 American hypogonadal men for up to 42 months; for the first 6 months, the study was a randomized, parallel trial of two doses of TTG and a transdermal patch; this was followed by 36 months of open-label study of TTG. Sexual function improved rapidly with TTG treatment, and changes were maintained throughout the 42-month study period. Steidle et al.
11 also compared a testosterone gel (AA2500) with a patch in 406 hypogonadal men at 43 US clinics in a 3-month, placebo-controlled study; 205 men received either of two doses of the transdermal gel. Compared with placebo, the gel significantly improved spontaneous erections, sexual desire and sexual motivation. In Germany, Schultheiss et al. 15 performed a pilot study of 46 hypogonadal men with ED for 6-8 weeks and reported a 32.6% success rate with improved erection.
The results from our double-blind, randomized, placebo-controlled trial is the first study conducted in Asian population that followed a standard clinical trial procedure, while those in the studies described above were data reported in western countries. We also used IIEF scores to measure improvement in sexual function. The largest American study from the Transdermal Gel Study Group 5, 7, 8 did not include a placebo group and did not use IIEF scores. Another American study 1 of 32 hypogonadal men with ED used IIEF scores to measure improvement in sexual function at 1, 3 and 6 months after normalization of serum testosterone levels with TTG or a transdermal patch. However, there was no placebo control in this study. The German pilot study 15 had neither a placebo control group nor used IIEF scores to measure sexual function.
AEs in this study were relatively higher than the studies in the United States and Germany. 8, 15 However, most of the events were short-term potentially drug-related and were transient with spontaneous recovery. No drug-related AEs was found in the TTG group. The drug-related AEs in this study were found in the placebo group and may be related to the vehicles of the testosterone. Although this is a shortterm, pilot study with relatively small sample size, the data from the current study are consistent with previous studies in other populations. However, long-term observation should be continued to assess the safety of this preparation (gel).
Our results demonstrated that TTG improves erectile dysfunction in Asian men with hypogonadism; however, a long-term study, such as 6 or 12 months, may be needed to clarify the issues. To our knowledge, our pilot study is the first trial of transdermal testosterone supplementation in hypogonadal men in Taiwan. Their improved scores on the IIEF index indicate that TTG effectively improved their erectile dysfunction. In addition, TTG was safe and well tolerated. There were no drug-related AEs, severe AEs or skin irritation reports in the TTG group.
Conclusions
TTG is an effective, well-absorbed, well-tolerated ART for hypogonadal men in Asian population. It effectively restored serum testosterone levels to a normal physiological range and improved the sexual function of these men with few AEs and without skin irritation.
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